Cardiovascular effects in childhood cancer survivors treated with anthracyclines

Cardiology Research and Practice

Volumn 1, Issue 1, 2011, Pages

  Lipshultz, Steven E ^a,b   Franco, Vivian I ^a   Henkel, Jacqueline M ^a   Miller, Tracie L ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE DERIVATIVE; C REACTIVE PROTEIN; CARDIOLIPIN; DOXORUBICIN; NEU DIFFERENTIATION FACTOR; RAZOXANE; TRASTUZUMAB; TROPONIN I; TROPONIN T;

ACUTE LYMPHOCYTIC LEUKEMIA; CALCIUM HOMEOSTASIS; CANCER PATIENT; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHILDHOOD CANCER; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DNA DAMAGE; DNA SYNTHESIS; DRUG INDUCED DISEASE; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HYPERTENSION; IMMOBILIZATION; INSULIN RESISTANCE; LONG TERM CARE; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SMOKING;

EID: 79959393878     PISSN: None     EISSN: 20900597     Source Type: Journal    
DOI: 10.4061/2011/134679     Document Type: Review

References (118)

1. Li J., Thompson T. D., Miller J. W., Pollack L. A., Stewart S. L., Cancer incidence among children and adolescents in the United States, 20012003 Pediatrics 2008 121 6 e1470 e1477
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., Thun M. J., Cancer statistics Ca-A Cancer Journal for Clinicians 2010 60 277 300
3. Silverman L. B., Stevenson K. E., O'Brien J. E., Asselin B. L., Barr R. D., Clavell L., Cole P. D., Kelly K. M., Laverdiere C., Michon B., Schorin M. A., Schwartz C. L., O'Holleran E. W., Neuberg D. S., Cohen H. J., Sallan S. E., Long-term results of dana-farber cancer institute all consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (19852000) Leukemia 2010 24 2 320 334
4. Mariotto A. B., Rowland J. H., Yabroff K. R., Scoppa S., Hachey M., Ries L., Feuer E. J., Long-term survivors of childhood cancers in the United States Cancer Epidemiology Biomarkers and Prevention 2009 18 4 1033 1040
5. Oeffinger K. C., Mertens A. C., Sklar C. A., Kawashima T., Hudson M. M., Meadows A. T., Friedman D. L., Marina N., Hobbie W., Kadan-Lottick N. S., Schwartz C. L., Leisenring W., Robison L. L., Chronic health conditions in adult survivors of childhood cancer The New England Journal of Medicine 2006 355 15 1572 1582 (Pubitemid 44547808)
6. Mertens A. C., Liu Q., Neglia J. P., Wasilewski K., Leisenring W., Armstrong G. T., Robison L. L., Yasui Y., Cause-specific late mortality among 5-year survivors of childhood cancer: the childhood cancer survivor study Journal of the National Cancer Institute 2008 100 19 1368 1379
7. Mulrooney D. A., Yeazel M. W., Kawashima T., Mertens A. C., Mitby P., Stovall M., Donaldson S. S., Green D. M., Sklar C. A., Robison L. L., Leisenring W. M., Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort British Medical Journal 2009 339 b4606
8. Mller T. R., Garwicz S., Barlow L., Winther J. F., Glattre E., Olafsdottir G., Olsen J. H., Perfekt R., Ritvanen A., Sankila R., Tulinius H., Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries Journal of Clinical Oncology 2001 19 13 3173 3181 (Pubitemid 32591433)
9. Tukenova M., Guibout C., Oberlin O., Doyon F., Mousannif A., Haddy N., Guérin S., Pacquement H., Aouba A., Hawkins M., Winter D., Bourhis J., Lefkopoulos D., Diallo I., de Vathaire F., Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer Journal of Clinical Oncology 2010 28 8 1308 1315
10. Lipshultz S. E., Adams M. J., Cardiotoxicity after childhood cancer: beginning with the end in mind Journal of Clinical Oncology 2010 28 8 1276 1281
11. Lipshultz S. E., Alvarez J. A., Scully R. E., Anthracycline associated cardiotoxicity in survivors of childhood cancer Heart 2008 94 4 525 533 (Pubitemid 351441417)
12. Reulen R. C., Winter D. L., Frobisher C., Lancashire E. R., Stiller C. A., Jenney M. E., Skinner R., Stevens M. C., Hawkins M. M., Long-term cause-specific mortality among survivors of childhood cancer Journal of the American Medical Association 2010 304 2 172 179
13. Levitt G., Anazodo A., Burch M., Bunch K., Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need? European Journal of Cancer 2009 45 17 3027 3034
14. Lipshultz S. E., Colan S. D., Gelber R. D., Perez-Atayde A. R., Sallan S. E., Sanders S. P., Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood The New England Journal of Medicine 1991 324 12 808 815
15. Adams M. J., Lipshultz S. E., Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention Pediatric Blood and Cancer 2005 44 7 600 606 (Pubitemid 40629208)
16. Giantris A., Abdurrahman L., Hinkle A., Asselin B., Lipshultz S. E., Anthracycline-induced cardiotoxicity in children and young adults Critical Reviews in Oncology/Hematology 1998 27 1 53 68 (Pubitemid 28275509)
17. Grenier M. A., Lipshultz S. E., Epidemiology of anthracycline cardiotoxicity in children and adults Seminars in Oncology 1998 25 4 72 85 (Pubitemid 28460388)
18. Barry E., Alvarez J. A., Scully R. E., Miller T. L., Lipshultz S. E., Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management Expert Opinion on Pharmacotherapy 2007 8 8 1039 1058 (Pubitemid 46929299)
19. Nysom K., Holm K., Lipsitz S. R., Mone S. M., Colan S. D., Orav E. J., Sallan S. E., Olsen J. H., Hertz H., Jacobsen J. R., Lipshultz S. E., Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia Journal of Clinical Oncology 1998 16 2 545 550 (Pubitemid 28135597)
20. Horenstein M. S., Vander Heide R. S., L'Ecuyer T. J., Molecular basis of anthracycline-induced cardiotoxicity and its prevention Molecular Genetics and Metabolism 2000 71 1-2 436 444
21. Lebrecht D., Setzer B., Ketelsen U. P., Haberstroh J., Walker U. A., Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy Circulation 2003 108 19 2423 2429 (Pubitemid 37413552)
22. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L., Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity Pharmacological Reviews 2004 56 2 185 229 (Pubitemid 38720829)
23. Gianni L., Herman E. H., Lipshultz S. E., Minotti G., Sarvazyan N., Sawyer D. B., Anthracycline cardiotoxicity: from bench to bedside Journal of Clinical Oncology 2008 26 22 3777 3784
24. imnek T., trba M., Popelov O., Adamcov M., Hrdina R., Geri V., Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron Pharmacological Reports 2009 61 1 154 171
25. Nicolay K., van der Neut R., Fok J. J., de Kruijff B., Effects of adriamycin on lipid polymorphism in cardiolipin-containing model and mitochondrial membranes Biochimica et Biophysica Acta 1985 819 1 55 65 (Pubitemid 15229786)
26. Leonard R. C. F., Williams S., Tulpule A., Levine A. M., Oliveros S., Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet ) Breast 2009 18 4 218 224
27. Ashley N., Poulton J., Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs Biochemical and Biophysical Research Communications 2009 378 3 450 455
28. Wallace K. B., Doxorubicin-induced cardiac mitochondrionopathy Pharmacology and Toxicology 2003 93 3 105 115 (Pubitemid 37108538)
29. Thompson K. L., Rosenzweig B. A., Zhang J., Knapton A. D., Honchel R., Lipshultz S. E., Retief J., Sistare F. D., Herman E. H., Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats Cancer Chemotherapy and Pharmacology 2010 66 2 303 314
30. Doroshow J. H., Locker G. Y., Myers C. E., Enzymatic defenses of the mouse heart against reactive oxygen metabolites. Alterations produced by doxorubicin Journal of Clinical Investigation 1980 65 1 128 135 (Pubitemid 10214339)
31. Ito H., Miller S. C., Billingham M. E., Akimoto H., Torti S. V., Wade R., Gahlmann R., Lyons G., Kedes L., Torti F. M., Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro Proceedings of the National Academy of Sciences of the United States of America 1990 87 11 4275 4279
32. Peng X., Chen B., Lim C. C., Sawyer D. B., The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine Molecular Interventions 2005 5 3 163 171 (Pubitemid 41018273)
33. Chen B., Peng X., Pentassuglia L., Lim C. C., Sawyer D. B., Molecular and cellular mechanisms of anthracycline cardiotoxicity Cardiovascular Toxicology 2007 7 2 114 121 (Pubitemid 47339857)
34. De Angelis A., Piegari E., Cappetta D., Marino L., Filippelli A., Berrino L., Ferreira-Martins J., Zheng H., Hosoda T., Rota M., Urbanek K., Kajstura J., Leri A., Rossi F., Anversa P., Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function Circulation 2010 121 2 276 292
35. Kalyanaraman B., Joseph J., Kalivendi S., Wang S., Konorev E., Kotamraju S., Doxorubicin-induced apoptosis: implications in cardiotoxicity Molecular and Cellular Biochemistry 2002 234-235 119 124 (Pubitemid 34777848)
36. Jurcut R., Wildiers H., Ganame J., D'hooge J., Paridaens R., Voigt J. U., Detection and monitoring of cardiotoxicitywhat does modern cardiology offer? Supportive Care in Cancer 2008 16 5 437 445
37. Rusconi P., Gmez-Marn O., Rossique-Gonzlez M., Redha E., Marn J. R., Lon-Young M., Wolff G. S., Carvedilol in children with cardiomyopathy: 3-Year experience at a single institution Journal of Heart and Lung Transplantation 2004 23 7 832 838 (Pubitemid 38953866)
38. Lowis S., Lewis I., Elsworth A., Weston C., Doz F., Vassal G., Bellott R., Robert J., Pein F., Ablett S., Pinkerton R., Frappaz D., A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours British Journal of Cancer 2006 95 5 571 580 (Pubitemid 44325896)
39. Lebrecht D., Kokkori A., Ketelsen U. P., Setzer B., Walker U. A., Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin Journal of Pathology 2005 207 4 436 444 (Pubitemid 43025692)
40. Ryberg M., Nielsen D., Cortese G., Nielsen G., Skovsgaard T., Andersen P. K., New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients Journal of the National Cancer Institute 2008 100 15 1058 1067
41. Tokarska-Schlattner M., Zaugg M., Zuppinger C., Wallimann T., Schlattner U., New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics Journal of Molecular and Cellular Cardiology 2006 41 3 389 405 (Pubitemid 44362995)
42. Lipshultz S. E., Scully R. E., Smith H. M., Serum cardiovascular growth factors during doxorubicin chemotherapy in children with leukemia Proceedings of the 5th World Congress of Paediatric Cardiology and Cardiac Surgery (PCCS '09) June 2009 Cairns, Australia. Cardiomyopathy Poster Session. PCCS2009 Program page 133
43. Von Hoff D. D., Rozencweig M., Layard M., Daunomycin induced cardiotoxicity in children and adults. A review of 110 cases American Journal of Medicine 1977 62 2 200 208 (Pubitemid 8042834)
44. Lipshultz S. E., Lipsitz S. R., Miller T. L., Late cardiac status in long-term survivors of childhood high-risk all 8 years after continuous or bolus infusion of doxorubicin: the DFCI Childhood ALL 91-01 Randomized Trial Journal of Clinical Oncology 2010 28 15, supplement 9513
45. Lipshultz S. E., Rifai N., Sallan S. E., Lipsitz S. R., Dalton V., Sacks D. B., Ottlinger M. E., Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury Circulation 1997 96 8 2641 2648 (Pubitemid 27451357)
46. Wang L., Weinshilboum R., Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions Oncogene 2006 25 11 1629 1638
47. Deng S., Wojnowski L., Genotyping the risk of anthracycline-induced cardiotoxicity Cardiovascular Toxicology 2007 7 2 129 134 (Pubitemid 47339859)
48. Blanco J. G., Leisenring W. M., Gonzalez-Covarrubias V. M., Kawashima T. I., Davies S. M., Relling M. V., Robison L. L., Sklar C. A., Stovall M., Bhatia S., Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQ01 in patients who developed anthracycline-related congestive heart failure after childhood cancer Cancer 2008 112 12 2789 2795 (Pubitemid 351969225)
49. Miranda C. J., Makui H., Soares R. J., Bilodeau M., Mui J., Vali H., Bertrand R., Andrews N. C., Santos M. M., Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin Blood 2003 102 7 2574 2580 (Pubitemid 37193598)
50. Krischer J. P., Epstein S., Cuthbertson D. D., Goorin A. M., Epstein M. L., Lipshultz S. E., Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience Journal of Clinical Oncology 1997 15 4 1544 1552 (Pubitemid 27167391)
51. Krischer J. P., Cuthbertson D. D., Epstein S., Goorin A. M., Epstein M. L., Lipshultz S. E., Risk factors for early anthracycline clinical cardiotoxicity in children: the pediatric oncology group experience Progress in Pediatric Cardiology 1997 8 2 83 90 (Pubitemid 28190025)
52. Establishing and enhancing services for childhood cancer survivors: long-term follow-up program resource guide. Childrens Oncology Group, 2007, http://www.survivorshipguidelines.org/
53. Lipshultz S. E., Scully R. E., Lipsitz S. R., Sallan S. E., Silverman L. B., Miller T. L., Barry E. V., Asselin B. L., Athale U., Clavell L. A., Larsen E., Moghrabi A., Samson Y., Michon B., Schorin M. A., Cohen H. J., Neuberg D. S., Orav E. J., Colan S. D., Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial The Lancet Oncology 2010 11 10 950 961
54. Cardinale D., Sandri M. T., Colombo A., Colombo N., Boeri M., Lamantia G., Civelli M., Peccatori F., Martinelli G., Fiorentini C., Cipolla C. M., Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 2004 109 22 2749 2754 (Pubitemid 38737923)
55. Cardinale D., Sandri M. T., Martinoni A., Tricca A., Civelli M., Lamantia G., Cinieri S., Martinelli G., Cipolla C. M., Fiorentini C., Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy Journal of the American College of Cardiology 2000 36 2 517 522
56. Lipshultz S. E., Wong J. C. L., Lipsitz S. R., Simbre V. C., Zareba K. M., Galpechian V., Rifai N., Frequency of clinically unsuspected myocardial injury at a children's hospital American Heart Journal 2006 151 4 916 922
57. Herman E. H., Zhang J., Lipshultz S. E., Rifai N., Chadwick D., Takeda K., Yu Z. X., Ferrans V. J., Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin Journal of Clinical Oncology 1999 17 7 2237 2243 (Pubitemid 29318858)
58. Lipshultz S. E., Rifai N., Dalton V. M., Levy D. E., Silverman L. B., Lipsitz S. R., Colan S. D., Asselin B. L., Barr R. D., Clavell L. A., Hurwitz C. A., Moghrabi A., Samson Y., Schorin M. A., Gelber R. D., Sallan S. E., The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia The New England Journal of Medicine 2004 351 2 145 153 (Pubitemid 38886649)
59. Lipshultz S. E., Miller T. L., Scully R. E., Diagnostic value of cardiac troponin T, N-terminal pro-brain natriuretic peptide, and high-sensitivity C-reactive protein during Doxorubicin therapy in children with acute lymphoblastic 6 leukemia Circulation 2010 122 21, supplement, A20432
60. Martinez-Rumayor A., Richards A. M., Burnett J. C., Januzzi J. L., Biology of the natriuretic peptides American Journal of Cardiology 2008 101 3 S3 S8
61. Wang T. J., Larson M. G., Levy D., Benjamin E. J., Leip E. P., Omland T., Wolf P. A., Vasan R. S., Plasma natriuretic peptide levels and the risk of cardiovascular events and death The New England Journal of Medicine 2004 350 7 655 663 (Pubitemid 38364624)
62. Kragelund C., Grnning B., Kber L., Hildebrandt P., Steffensen R., N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease The New England Journal of Medicine 2005 352 7 666 675 (Pubitemid 40239214)
63. Grewal J., McKelvie R. S., Persson H., Tait P., Carlsson J., Swedberg K., Ostergren J., Lonn E., Usefulness of N-terminal probrain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction American Journal of Cardiology 2008 102 6 733 737
64. Black S., Kushner I., Samols D., C-reactive protein The Journal of Biological Chemistry 2004 279 47 48487 48490 (Pubitemid 39625721)
65. Ratnasamy C., Kinnamon D. D., Lipshultz S. E., Associations between neurohormonal and inflammatory activation and heart failure in children Progress in Pediatric Cardiology 2007 24 81 82
66. Singh S. K., Suresh M. V., Voleti B., Agrawal A., The connection between C-reactive protein and atherosclerosis Annals of Medicine 2008 40 2 110 120 (Pubitemid 351640645)
67. Lipshultz S. E., Lipsitz S. R., Hinkle A. S., Cardiovascular status, subsequent risk, and associated factors in long-term survivors of childhood cancer in a population-based NCI study Circulation 2005 112 supplement 2 476
68. Petricoin E., Ross M. M., Zhou W., Candidate serum biomarkers of doxorubicin-induced cardiotoxicity in pediatric acute lymphoblastic leukemia assessed by nanoparticle-capture mass spectrometry Journal of Clinical Oncology 2010 28 9528
69. Lipshultz S. E., Lipsitz S. R., Sallan S. E., Dalton V. M., Mone S. M., Gelber R. D., Colan S. D., Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia Journal of Clinical Oncology 2005 23 12 2629 2636 (Pubitemid 46179451)
70. Lipshultz S. E., Lipsitz S. R., Mone S. M., Goorin A. M., Sallan S. E., Sanders S. P., Orav E. J., Gelber R. D., Colan S. D., Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer The New England Journal of Medicine 1995 332 26 1738 1743
71. Lipshultz S. E., Colan S. D., Cardiovascular trials in long-term survivors of childhood cancer Journal of Clinical Oncology 2004 22 5 769 773 (Pubitemid 41103586)
72. Sorensen K., Levitt G. A., Bull C., Dorup I., Sullivan I. D., Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study Cancer 2003 97 8 1991 1998 (Pubitemid 36397277)
73. Ganame J., Claus P., Uyttebroeck A., Renard M., D'hooge J., Bijnens B., Sutherland G. R., Eyskens B., Mertens L., Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients Journal of the American Society of Echocardiography 2007 20 12 1351 1358 (Pubitemid 350181316)
74. Nysom K., Colan S. D., Lipshultz S. E., Late cardiotoxicity following anthracycline therapy for childhood cancer Progress in Pediatric Cardiology 1998 8 3 121 138 (Pubitemid 28200698)
75. Schorin M. A., Blattner S., Gelber R. D., Tarbell N. J., Donnelly M., Dalton V., Cohen H. J., Sallan S. E., Treatment of childhood acute lymphoblastic leukemia: results of Dana- Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85-01 Journal of Clinical Oncology 1994 12 4 740 747
76. Fulbright J. M., Huh W., Anderson P., Chandra J., Can anthracycline therapy for pediatric malignancies be less cardiotoxic? Current Oncology Reports 2010 12 6 411 419
77. Gabizon A. A., Lyass O., Berry G. J., Wildgust M., Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies Cancer Investigation 2004 22 5 663 669 (Pubitemid 40064725)
78. Marina N. M., Cochrane D., Harney E., Zomorodi K., Blaney S., Winick N., Bernstein M., Link M. P., Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study Clinical Cancer Research 2002 8 2 413 418 (Pubitemid 34193958)
79. Levitt G. A., Dorup I., Sorensen K., Sullivan I., Does anthracycline administration by infusion in children affect late cardiotoxicity? British Journal of Haematology 2004 124 4 463 468 (Pubitemid 38230590)
80. Gupta M., Steinherz P. G., Cheung N. K., Steinherz L., Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers Medical and Pediatric Oncology 2003 40 6 343 347 (Pubitemid 36514435)
81. Wouters K. A., Kremer L. C. M., Miller T. L., Herman E. H., Lipshultz S. E., Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies British Journal of Haematology 2005 131 5 561 578 (Pubitemid 43899624)
82. Lipshultz S. E., Giantris A. L., Lipsitz S. R., Dalton V. K., Asselin B. L., Barr R. D., Clavell L. A., Hurwitz C. A., Moghrabi A., Samson Y., Schorin M. A., Gelber R. D., Sallan S. E., Colan S. D., Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol Journal of Clinical Oncology 2002 20 6 1677 1682 (Pubitemid 34260550)
83. Lipshultz S. E., Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children Journal of Clinical Oncology 1996 14 2 328 331 (Pubitemid 26050991)
84. Tebbi C. K., London W. B., Friedman D., Villaluna D., De Alarcon P. A., Constine L. S., Mendenhall N. P., Sposto R., Chauvenet A., Schwartz C. L., Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease Journal of Clinical Oncology 2007 25 5 493 500 (Pubitemid 350002954)
85. Lipshultz S. E., Lipsitz S. R., Orav E. J., Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence Journal of Clinical Oncology 2007 25 21 3179. author reply 3180 (Pubitemid 47218071)
86. Hellmann K., Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence Journal of Clinical Oncology 2007 25 29 4689 4690 (Pubitemid 350035331)
87. Barry E. V., Vrooman L. M., Dahlberg S. E., Neuberg D. S., Asselin B. L., Athale U. H., Clavell L. A., Larsen E. C., Moghrabi A., Samson Y., Schorin M. A., Cohen H. J., Lipshultz S. E., Sallan S. E., Silverman L. B., Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane Journal of Clinical Oncology 2008 26 7 1106 1111
88. Herman E., Knapton A., Zhang J., Hiraragi H., Lipshultz S. E., Gender is a factor that can impact the severity of doxorubicin (DXR) toxicity in spontaneously hypertensive rats (SHR) The FASEB Journal 2008 22 719.6
89. Williams R. V., Tani L. Y., Shaddy R. E., Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction Journal of Heart and Lung Transplantation 2002 21 8 906 909 (Pubitemid 34876933)
90. Thompson P. A., Rosner G. L., Matthay K. K., Moore T. B., Bomgaars L. R., Ellis K. J., Renbarger J., Berg S. L., Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study Cancer Chemotherapy and Pharmacology 2009 64 2 243 251
91. Schuetz E. G., Furuya K. N., Schuetz J. D., Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms Journal of Pharmacology and Experimental Therapeutics 1995 275 2 1011 1018 (Pubitemid 26023635)
92. Belhani D., Fanton L., Vaillant F., Descotes J., Manati W., Tabib A., Bui-Xuan B., Timour Q., Cardiac lesions induced by testosterone: protective effects of dexrazoxane and trimetazidine Cardiovascular Toxicology 2009 9 2 64 69
93. Kremer L. C. M., van Dalen E. C., Offringa M., Vote P. A., Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review Annals of Oncology 2002 13 4 503 512 (Pubitemid 34461132)
94. LeClerc J. M., Billett A. L., Gelber R. D., Dalton V., Tarbell N., Lipton J. M., Barr R., Clavell L. A., Asselin B., Hurwitz C., Schorin M., Lipshultz S. E., Declerck L., Silverman L. B., Cohen H. J., Sallan S. E., Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01 Journal of Clinical Oncology 2002 20 1 237 246 (Pubitemid 34032617)
95. Lipshultz S. E., Wilkinson J. D., Messiah S. E., Miller T. L., Clinical research directions in pediatric cardiology Current Opinion in Pediatrics 2009 21 5 585 593
96. Ogden C. L., Carroll M. D., Curtin L. R., McDowell M. A., Tabak C. J., Flegal K. M., Prevalence of overweight and obesity in the United States, 19992004 Journal of the American Medical Association 2006 295 13 1549 1555
97. Whitaker R. C., Wright J. A., Pepe M. S., Seidel K. D., Dietz W. H., Predicting obesity in young adulthood from childhood and parental obesity The New England Journal of Medicine 1997 337 13 869 873 (Pubitemid 27408568)
98. Messiah S. E., Arheart K. L., Luke B., Lipshultz S. E., Miller T. L., Relationship between body mass index and metabolic risk factors among US 8- to 14-year olds, 19992002 Journal of Pediatrics 2008 153 2 215 221
99. Daniels S. R., Jacobson M. S., McCrindle B. W., Eckel R. H., Sanner B. M., American heart association childhood obesity: research summit Circulation 2009 119 15 2114 2123
100. Meacham L. R., Gurney J. G., Mertens A. C., Ness K. K., Sklar C. A., Robison L. L., Oeffinger K. C., Body mass index in long-term adult survivors of childhood cancer: a report of the childhood cancer survivor study Cancer 2005 103 8 1730 1739 (Pubitemid 40490036)
101. Nathan P. C., Jovcevska V., Ness K. K., Mammone D'Agostino N., Staneland P., Urbach S. L., Barron M., Barrera M., Greenberg M. L., The prevalence of overweight and obesity in pediatric survivors of cancer Journal of Pediatrics 2006 149 4 518 525.e2
102. Miller T. L., Lipsitz S. R., Lopez-Mitnik G., Hinkle A. S., Constine L. S., Adams M. J., French C., Proukou C., Rovitelli A., Lipshultz S. E., Characteristics and determinants of adiposity in pediatric cancer survivors Cancer Epidemiology Biomarkers and Prevention 2010 19 8 2013 2022
103. Razzouk B. I., Rose S. R., Hongeng S., Wallace D., Smeltzer M. P., Zacher M., Pui C. H., Hudson M. M., Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma Journal of Clinical Oncology 2007 25 10 1183 1189 (Pubitemid 46646518)
104. McCambridge T. M., Bernhardt D. T., Brenner J. S., Congeni J. A., Gomez J. E., Gregory A. J.M., Gregory D. B., Griesemer B. A., Reed F. E., Rice S. G., Small E. W., Stricker P. R., LeBlanc C., Raynor J., Lindros J. C., Frankowski B. L., Gereige R. S., Grant L. M., Hyman D., Magalnick H., Mears C. J., Monteverdi G. J., Murray R. D., Pattishall III E. G., Roland M. M., Young T. L., LaCursia N., Vernon-Smiley M., Mazyck D., Wallace R., Li S., Active healthy living: prevention of childhood obesity through increased physical activity Pediatrics 2006 117 5 1834 1842 (Pubitemid 46071420)
105. US Department of Health and Human Services (USDHHS), Physical Activity Guidelines Advisory Committee Report, 2008 2008 Washington, DC, USA US Department of Health and Human Services
106. Ness K. K., Leisenring W. M., Huang S., Hudson M. M., Gurney J. G., Whelan K., Hobbie W. L., Armstrong G. T., Robison L. L., Oeffinger K. C., Predictors of inactive lifestyle among adult survivors of childhood cancer Cancer 2009 115 9 1984 1994
107. Cox C. L., Montgomery M., Oeffinger K. C., Leisenring W., Zeltzer L., Whitton J. A., Mertens A. C., Hudson M. M., Robison L. L., Promoting physical activity in childhood cancer survivors Cancer 2009 115 3 642 654
108. Doll R., Peto R., Mortality in relation to smoking: 20 years' observations on male British doctors British Medical Journal 1976 2 6051 1525 1536 (Pubitemid 8005177)
109. Clarke S. A., Eiser C., Health behaviours in childhood cancer survivors: a systematic review European Journal of Cancer 2007 43 9 1373 1384 (Pubitemid 46874064)
110. Centers for Disease Control and Prevention (CDC), Cigarette smoking among adults and trends in smoking cessationUnited States, 2008 Morbidity and Mortality Weekly Report 2009 58 1227 1232
111. Emmons K., Li F. P., Whitton J., Mertens A. C., Hutchinson R., Diller L., Robison L. L., Predictors of smoking initiation and cessation among childhood cancer survivors: a report from the Childhood Cancer Survivor Study Journal of Clinical Oncology 2002 20 6 1608 1616 (Pubitemid 34260542)
112. Emmons K. M., Puleo E., Mertens A., Gritz E. R., Diller L., Li F. P., Long-term smoking cessation outcomes among childhood cancer survivors in the partnership for health study Journal of Clinical Oncology 2009 27 1 52 60
113. Cowie C. C., Rust K. F., Ford E. S., Eberhardt M. S., Byrd-Holt D. D., Li C., Williams D. E., Gregg E. W., Bainbridge K. E., Saydah S. H., Geiss L. S., Full accounting of diabetes and pre-diabetes in the U.S. population in 19881994 and 2005-2006 Diabetes Care 2009 32 2 287 294
114. Meacham L. R., Sklar C. A., Li S., Liu QI., Gimpel N., Yasui Y., Whitton J. A., Stovall M., Robison L. L., Oeffinger K. C., Diabetes mellitus in long-term survivors of childhood cancerincreased risk associated with radiation therapy: a report for the childhood cancer survivor study Archives of Internal Medicine 2009 169 15 1381 1388
115. Neville K. A., Cohn R. J., Steinbeck K. S., Johnston K., Walker J. L., Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: prevalence and risk factors Journal of Clinical Endocrinology and Metabolism 2006 91 11 4401 4407 (Pubitemid 44833416)
116. Egan B. M., Zhao Y., Axon R. N., US trends in prevalence, awareness, treatment, and control of hypertension, 19882008 Journal of the American Medical Association 2010 303 20 2043 2050
117. Herman E. H., El-Hage A. N., Ferrans V. J., Ardalan B., Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats Toxicology and Applied Pharmacology 1985 78 2 202 214 (Pubitemid 15081080)
118. Hershman D. L., McBride R. B., Eisenberger A., Wei Y. T., Grann V. R., Jacobson J. S., Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma Journal of Clinical Oncology 2008 26 19 3159 3165